Literature DB >> 1721360

Quality-of-life advantages of FK 506 vs conventional immunosuppressive drug therapy in cardiac transplantation.

M A Dew1, R C Harris, R G Simmons, L H Roth, J M Armitage, B P Griffith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1721360

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  6 in total

Review 1.  FK 506 versus cyclosporine.

Authors:  T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

2.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 3.  Tacrolimus: in heart transplant recipients.

Authors:  Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.

Authors:  C M Spencer; K L Goa; J C Gillis
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

5.  Clinical trial of FK 506 immunosuppression in adult cardiac transplantation.

Authors:  J M Armitage; R L Kormos; S Morita; J Fung; G C Marrone; R L Hardesty; B P Griffith; T E Starzl
Journal:  Ann Thorac Surg       Date:  1992-08       Impact factor: 4.330

6.  Reliability and validity of the ESRD Symptom Checklist--Transplantation Module in Norwegian kidney transplant recipients.

Authors:  Knut Stavem; Rüdiger Ganss
Journal:  BMC Nephrol       Date:  2006-11-16       Impact factor: 2.388
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.